Core Viewpoint - The stock of Plater Technology has shown significant volatility, with a year-to-date increase of 84.21%, but a recent decline of 8.89% over the last five trading days [1] Company Overview - Plater Technology, established on July 6, 2011, and listed on July 22, 2019, is based in Xi'an, Shaanxi Province, and specializes in providing comprehensive solutions for metal additive manufacturing (3D printing) and remanufacturing technology [1] - The company's main revenue sources include customized 3D printing products and technical services (52.01%), 3D printing equipment, accessories, and technical services (41.14%), and 3D printing raw materials (6.85%) [1] Financial Performance - For the first half of 2025, Plater Technology achieved a revenue of 667 million yuan, representing a year-on-year growth of 17.22%, and a net profit attributable to shareholders of 76.31 million yuan, up by 9.98% [2] - Since its A-share listing, the company has distributed a total of 82.67 million yuan in dividends, with 66.51 million yuan distributed over the past three years [3] Shareholder Information - As of June 30, 2025, the number of shareholders of Plater Technology increased by 27.74% to 13,100, with an average of 20,671 circulating shares per person, a decrease of 21.72% [2] - Among the top ten circulating shareholders, Invesco Great Wall Research Select Stock A (000688) is the fourth largest, holding 6.39 million shares, down by 1.82 million shares from the previous period [3] Market Activity - On September 5, the stock price rose by 2.01% to 72.43 yuan per share, with a trading volume of 277 million yuan and a turnover rate of 1.42%, resulting in a total market capitalization of 19.684 billion yuan [1] - The stock has appeared on the daily trading list three times this year, with the most recent net purchase on July 3 amounting to 53.13 million yuan [1]

Core Viewpoint - 甘李药业 has shown significant growth in stock price and financial performance, indicating strong market interest and operational success [1][2]. Financial Performance - As of June 30, 甘李药业 reported a revenue of 2.067 billion yuan, representing a year-on-year increase of 57.18% [2]. - The net profit attributable to shareholders reached 604 million yuan, marking a substantial growth of 101.96% compared to the previous year [2]. - Cumulatively, the company has distributed 1.612 billion yuan in dividends since its A-share listing, with 1.018 billion yuan distributed over the last three years [3]. Stock Performance - The stock price of 甘李药业 increased by 69.72% year-to-date, with a recent 5-day increase of 0.32%, a 20-day increase of 19.00%, and a 60-day increase of 31.04% [1]. - The stock was trading at 73.16 yuan per share, with a market capitalization of 43.974 billion yuan as of September 5 [1]. Shareholder Structure - As of June 30, the number of shareholders increased to 77,300, up by 3.08% from the previous period [2]. - The average number of circulating shares per shareholder decreased by 2.99% to 7,165 shares [2]. - Major shareholders include Hong Kong Central Clearing Limited, which increased its holdings by 174,800 shares, and new entrants like Innovation Drug and Southern Alpha Mixed A [3].

Company Overview - 康希诺生物股份公司 is located in Tianjin Economic-Technological Development Area and was established on January 13, 2009. The company went public on August 13, 2020. Its main business involves the research, production, and commercialization of innovative vaccines that meet both Chinese and international standards [1][2]. Financial Performance - As of June 30, 康希诺 reported a revenue of 382 million yuan for the first half of 2025, representing a year-on-year growth of 26% [2]. - The company recorded a net profit attributable to shareholders of -13.49 million yuan, which is a 94.02% increase compared to the previous period [2]. - Since its A-share listing, 康希诺 has distributed a total of 198 million yuan in dividends, with no dividends paid in the last three years [3]. Stock Performance - On September 5, 康希诺's stock price increased by 2.01%, reaching 81.30 yuan per share, with a trading volume of 84.25 million yuan and a turnover rate of 0.91%. The total market capitalization is 20.118 billion yuan [1]. - Year-to-date, 康希诺's stock price has risen by 33.17%, but it has seen a decline of 1.38% over the last five trading days and 2.93% over the last 20 days. In the last 60 days, the stock price increased by 34.49% [1]. Shareholder Information - As of June 30, 康希诺 had 17,500 shareholders, a decrease of 1.92% from the previous period. The average number of circulating shares per shareholder remains at 0 [2]. Business Segments - The company's main revenue source comes from vaccine and related product sales, accounting for 97.84% of total revenue, while other supplementary income constitutes 2.16% [1]. - 康希诺 operates within the pharmaceutical and biological industry, specifically in the vaccine sector, and is involved in concepts such as anti-influenza and monkeypox [1].

Core Viewpoint - Tongcheng New Materials has shown a mixed performance in stock price and financial results, with a slight increase in revenue and profit year-on-year, but recent stock price fluctuations indicate potential volatility in the market [1][2]. Financial Performance - As of June 30, 2025, Tongcheng New Materials achieved a revenue of 1.655 billion yuan, representing a year-on-year growth of 4.97% [2]. - The net profit attributable to shareholders for the same period was 351 million yuan, reflecting a year-on-year increase of 12.07% [2]. - Cumulative cash dividends since the company's A-share listing amount to 1.493 billion yuan, with 847 million yuan distributed over the past three years [3]. Stock Performance - On September 5, the stock price of Tongcheng New Materials rose by 2.03%, reaching 34.71 yuan per share, with a trading volume of 158 million yuan [1]. - The stock has seen a year-to-date increase of 0.69%, a decline of 4.96% over the last five trading days, a rise of 5.05% over the last 20 days, and an increase of 13.58% over the last 60 days [1]. Shareholder Information - As of June 30, 2025, the number of shareholders for Tongcheng New Materials was 47,200, a decrease of 2.84% from the previous period [2]. - The average number of circulating shares per shareholder increased by 2.93% to 12,618 shares [2]. - The top ten circulating shareholders include Hong Kong Central Clearing Limited and Southern CSI 500 ETF, with both increasing their holdings compared to the previous period [3]. Business Overview - Tongcheng New Materials, established on June 4, 2008, and listed on June 27, 2018, is primarily engaged in the research, production, sales, and trade of fine chemical materials [1]. - The company's main revenue sources include self-produced phenolic resin (54.46%), electronic materials (22.77%), and other products [1]. - The company operates within the basic chemical industry, specifically in rubber and rubber additives, and is involved in sectors such as OLED, new materials, and semiconductors [1].

Core Viewpoint - Nocera Health experienced a stock price decline of 2.02% on September 5, 2023, with a current price of 27.15 CNY per share, despite a year-to-date increase of 121.09% [1] Company Overview - Nocera Health, established on November 3, 2015, and listed on September 21, 2022, is based in Beijing and focuses on the research, production, and commercialization of biopharmaceuticals, particularly in oncology and autoimmune diseases [1] - The company's revenue composition includes 87.67% from drug sales, 12.04% from technology licensing, and 0.15% each from testing and R&D services [1] Financial Performance - For the first half of 2025, Nocera Health reported a revenue of 731 million CNY, reflecting a year-on-year growth of 74.26%, while the net profit attributable to shareholders was -30.09 million CNY, an increase of 88.51% year-on-year [2] Shareholder Information - As of June 30, 2025, the number of shareholders increased by 13.80% to 15,200, with an average of 0 circulating shares per shareholder [2] - The top ten circulating shareholders include notable funds such as China Europe Medical Health Mixed A and E Fund Precision Medical Flexible Allocation Mixed A, with changes in their holdings noted [3]

Company Overview - Weijie Chuangxin (Tianjin) Electronic Technology Co., Ltd. specializes in the research, design, and sales of RF front-end chips, primarily providing RF power amplifier module products, RF switch chips, Wi-Fi RF front-end modules, and receiver modules for various wireless communication devices [2][3] - The company's main business revenue composition includes RF power amplifier modules (79.96%), receiver modules (19.75%), and other (0.29%) [2] Financial Performance - For the first half of 2025, Weijie Chuangxin achieved operating revenue of 987 million yuan, a year-on-year decrease of 7.93%, and a net profit attributable to the parent company of -9.43 million yuan, a year-on-year decrease of 183.72% [2] - Since its A-share listing, the company has distributed a total of 23.01 million yuan in dividends [3] Stock Performance - As of September 5, the stock price of Weijie Chuangxin was 32.77 yuan per share, with a market capitalization of 14.101 billion yuan [1] - The stock has seen a year-to-date decline of 2.06%, a 6.77% drop over the last five trading days, and a 14.74% increase over the last 60 days [1] - The company has appeared on the trading leaderboard twice this year, with the most recent instance on April 11, where it recorded a net purchase of 5.6415 million yuan [1] Shareholder Information - As of June 30, 2025, the number of shareholders increased by 17.92% to 12,400, with an average of 12,951 circulating shares per person, up by 19.78% [2] - Notable institutional shareholders include Noan Growth Mixed Fund and Jiashi Shanghai Stock Exchange Science and Technology Innovation Board Chip ETF, with changes in their holdings reported [3]

Company Overview - Jingwang Electronics, established on March 9, 1993, and listed on January 6, 2017, is located in Shenzhen, Guangdong Province, specializing in the research, production, and sales of printed circuit boards (PCBs) [1][2] - The company's main business revenue composition is 94.67% from printed circuit boards and 5.33% from other supplementary services [1] Stock Performance - As of September 5, the stock price of Jingwang Electronics increased by 2.02% to 53.08 CNY per share, with a total market capitalization of 50.043 billion CNY [1] - Year-to-date, the stock price has risen by 96.30%, but it has seen a decline of 16.92% in the last five trading days and 10.97% over the last 20 days [1] - The stock has appeared on the daily trading leaderboard five times this year, with the most recent instance on September 2, where it recorded a net buy of -50.4725 million CNY [1] Financial Performance - For the first half of 2025, Jingwang Electronics reported a revenue of 7.095 billion CNY, representing a year-on-year growth of 20.93%, while the net profit attributable to shareholders decreased by 1.06% to 650 million CNY [2] - The company has distributed a total of 3.057 billion CNY in dividends since its A-share listing, with 1.593 billion CNY distributed in the last three years [3] Shareholder Structure - As of June 30, 2025, the number of shareholders decreased by 15.29% to 41,600, with an average of 22,190 circulating shares per shareholder, an increase of 18.29% [2] - Notable institutional shareholders include Hong Kong Central Clearing Limited, which holds 12.1388 million shares, and Southern CSI 500 ETF, which increased its holdings by 2.3751 million shares [3]

Core Viewpoint - Morning Glory Co., Ltd. has experienced a decline in stock price and revenue, indicating potential challenges in its business performance and market position [1][2]. Group 1: Stock Performance - On September 5, Morning Glory's stock price fell by 2.02%, reaching 29.65 CNY per share, with a total market capitalization of 27.307 billion CNY [1]. - Year-to-date, the stock price has increased by 1.34%, but it has decreased by 2.66% over the last five trading days, 5.12% over the last twenty days, and 10.59% over the last sixty days [1]. Group 2: Financial Performance - For the first half of 2025, Morning Glory reported a revenue of 10.809 billion CNY, a year-on-year decrease of 2.19%, and a net profit attributable to shareholders of 557 million CNY, down 11.97% year-on-year [2]. - Cumulatively, the company has distributed 4.701 billion CNY in dividends since its A-share listing, with 2.117 billion CNY distributed over the last three years [3]. Group 3: Shareholder Information - As of June 30, 2025, the number of shareholders increased to 39,200, with an average of 23,516 circulating shares per shareholder, a decrease of 1.84% from the previous period [2]. - The top shareholders include Invesco Great Wall New Growth Mixed Fund and Hong Kong Central Clearing Limited, with significant holdings remaining stable or increasing [3].

Core Viewpoint - Huaxia Airlines has shown a significant increase in revenue and net profit for the first half of 2025, indicating strong financial performance and growth potential in the aviation sector [2]. Group 1: Stock Performance - On September 5, Huaxia Airlines' stock rose by 2.02%, reaching 9.09 yuan per share, with a total market capitalization of 11.619 billion yuan [1]. - Year-to-date, the stock price has increased by 17.14%, while it has seen a slight decline of 1.20% over the last five trading days [1]. - The stock has experienced a 5.21% increase over the past 20 days and an 11.53% increase over the past 60 days [1]. Group 2: Financial Performance - For the period from January to June 2025, Huaxia Airlines reported a revenue of 3.610 billion yuan, representing a year-on-year growth of 12.41% [2]. - The net profit attributable to shareholders reached 251 million yuan, showing a remarkable year-on-year increase of 858.95% [2]. - Cumulative cash dividends since the A-share listing amount to 209 million yuan, with no dividends distributed in the past three years [2]. Group 3: Shareholder and Institutional Holdings - As of June 30, 2025, the number of shareholders for Huaxia Airlines decreased by 14.08% to 22,200, while the average number of circulating shares per person increased by 16.38% to 57,578 shares [2]. - The top ten circulating shareholders include several funds, with notable changes in holdings, such as Zhonggeng Value Pioneer Stock reducing its stake by 9.2025 million shares [2].

Core Viewpoint - 弘业期货 has shown a significant increase in stock price and trading volume, indicating potential investor interest and market activity [1] Company Overview - 弘业期货股份有限公司 primarily engages in commodity futures brokerage, financial futures brokerage, futures investment consulting, asset management, fund sales, and financial asset investment [2][7] - The company is the first A+H share listed company in the futures industry [2] - As of June 30, 2025, 弘业期货 reported a total revenue of 0.00 yuan and a net profit of -3.61 million yuan, a year-on-year decrease of 128.17% [7] Ownership and Control - 弘业期货 is a state-owned enterprise, ultimately controlled by the Jiangsu Provincial Government State-owned Assets Supervision and Administration Commission [3] Financial Performance - The company has a market capitalization of 11.87 billion yuan and a trading volume of 298 million yuan with a turnover rate of 3.34% [1] - The average trading cost of the stock is 12.84 yuan, with the current stock price near a resistance level of 11.84 yuan [6] Shareholder Information - As of June 30, 2025, the number of shareholders increased by 43.72% to 62,600 [7] - The top ten circulating shareholders include Hong Kong Central Clearing Limited and Southern CSI 1000 ETF, with notable increases in their holdings [8]